Lenalidomide Ratiopharm

Lenalidomide, the active ingredient in Lenalidomide Ratiopharm, is an immunomodulatory drug (IMiD) presented as an oral tablet for systemic use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier, serving hospitals, oncology centres and pharmacies worldwide with reliable sourcing and regulatory support. Our network ensures timely delivery and adherence to local import requirements. We maintain strict quality control throughout the supply chain.

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic marrow. - Multiple Myeloma: improves progression‑free survival and overall response when combined with dexamethasone or other agents. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. - Mantle Cell Lymphoma: used in relapsed or refractory disease to achieve disease control.

Lenalidomide may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require hydration. - Nausea: mild to moderate upset stomach. - Rash: skin erythema or mild itching. - Cytopenias: reduced blood cell counts, especially neutropenia and thrombocytopenia.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: increased infection risk. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: elevated liver enzymes or liver injury.

Before initiating Lenalidomide therapy, several safety considerations should be reviewed. - Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception. - Thromboembolic risk: assess need for prophylactic anticoagulation. - Renal function: dose may require adjustment in impaired kidney function. - Hepatic function: monitor liver enzymes in patients with liver disease. - Infection monitoring: watch for signs of infection due to neutropenia. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Lenalidomide can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure. - Anticoagulants (warfarin, DOACs): increased risk of bleeding when combined with lenalidomide‑induced thrombocytopenia.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity. - Vaccines: live vaccines should be avoided during treatment. - NSAIDs: may increase risk of renal impairment when combined with lenalidomide. - Hormonal contraceptives: effectiveness may be reduced; use additional barrier methods.